A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients

OBJECTIVES: To compare the efficacy and safety of two filgrastim formulations for controlling chemotherapy-induced neutropenia and to evaluate the non-inferiority of the test drug relative to the originator. METHODS: This phase III non-inferiority study had a randomized, multicenter, and open-label...

Descripción completa

Detalles Bibliográficos
Autores principales: Hegg, Roberto, Mattar, André, de Matos, João Nunes, Pedrini, José Luiz, Aleixo, Sabina Bandeira, Rocha, Roberto Odebrecht, Cramer, Renato Peixoto, van-Eyll-Rocha, Sylvie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2016
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054975/
https://www.ncbi.nlm.nih.gov/pubmed/27759847
http://dx.doi.org/10.6061/clinics/2016(10)06

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054975/
https://www.ncbi.nlm.nih.gov/pubmed/27759847
http://dx.doi.org/10.6061/clinics/2016(10)06

Ejemplares similares